Amarin Corp Plc (AMRN)

[couldbebetter]

MDCO was picked up by Novartis for around $10 billion, without even them
having completed their CVOT. AIMT of course by Nestles. Either company
could easily afford acquiring AMRN. Vascepa is still an amazing
Cardiovascular drug that SHOULD have even more importance in a COVID-19
world. Europe has a graying population and Vascepa should become a
heavily used medication if the pricing is low enough for that market.
For the right BP that truly understands the benefits it should be a
"must have" product. Novo Nordisk is very big into Diabetes...how
could they ignore Vascepa? The same holds true for Novartis...Imagine
the value of their PCSK-9 twice a year injectable along with Vascepa?
(That prospect should have Amgen very worried.) The only thing worse
than a BP missing out on acquiring AMRN will be to have a competitor
acquire AMRN.